.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,027,859

« Back to Dashboard

Claims for Patent: 7,027,859

Title:Electrotransport delivery device having improved safety and reduced abuse potential
Abstract:An electrotransport device (20) for delivering one or more therapeutic agents through the skin includes electrodes (30,32) for contacting the skin (34), at least one electrode containing the agent, a power source (22) for generating electrical current (I.sub.L) for delivering the agent, a current generating and controlling means (24), and a disabling means (26) for permanently and irreversibly disabling the current. The disabling means (26) may include a timer means (66), a counter means (82), or a body parameter sensor (134) and limit comparator (132) to effect permanent disabling. The disabling means may be a permanent transition to a disabled logic state, a permanent discharge of a power supply source (22), or a permanent diversion of electrotransport current from the electrodes (30,32), or a combination of the above. The permanent disabling means may include a circuit connection means (304,308,326,328) having a frangible conducting member (332) which permanently fractures and causes an irreversible open circuit in the connection to the electrodes (334,342) upon removing a disposable/single use electrode assembly (300) from a reusable portion of an electrotransport device.
Inventor(s): McNichols; Larry A. (Coon Rapids, MN), Badzinski; John D. (Coon Rapids, MN), Reining; William N. (Cross Plains, WI), Lattin; Gary A. (Forest Lake, MN), Haak; Ronald P (Menlo Park, CA), Phipps; Joseph B. (Plymouth, MN)
Assignee: ALZA Corporation (Mountain View, CA)
Application Number:08/312,336
Patent Claims: 1. An electrotransport device for delivering a therapeutic agent, comprising: a power source; first and second electrodes and reservoirs, wherein at least one of the reservoirs contains the therapeutic agent; a current generating circuit; a current controlling circuit; a current enabling circuit; a current disabling circuit adapted to automatically, permanently and irreversibly disable the current generating circuit upon occurrence of a predetermined event, thereby discontinuing electrotransportation of the agent from the device, said current disabling circuit including a timer circuit, wherein said predetermined event is the expiration of a period of time establishing by said timer circuit; and a current discharging circuit including a silicon controlled rectifier or a field effect transistor.

2. The device of claim 1, wherein said period of time is from initiation of said timer circuit to a shelf-life.

3. The device of claim 1, wherein the therapeutic agent comprises an abusable drug.

4. The device of claim 3, wherein the abusable drug is a narcotic analgesic.

5. The device of claim 3, wherein said abusable drug is a member selected from the group consisting of fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihydrocodeinone and cocaine.

6. The device of claim 1, wherein the timer circuit can be set to after a predetermined period of time fire a silicon controlled rectifier to discharge a battery to permanently and irreversibly disable the current generating circuit.

7. The method of claim 6, wherein the silicon controlled rectifier is connected to a resistor to discharge the battery.

8. A method of delivering a therapeutic agent by electrotransport, comprising the steps of: providing an electrotransport device for delivering a therapeutic agent comprising: a power source; first and second electrodes and reservoirs, wherein at least one of the reservoirs contains the therapeutic agent; a current generating circuit; a current controlling circuit; a current enabling circuit; a discharging circuit including a silicon controlled rectifier or a field effect transistor and a current disabling circuit including a timer circuit adapted to automatically, permanently and irreversibly disable the current generating circuit upon occurrence of a predetermined event, thereby discontinuing electrotransportation of the agent from the device; and automatically, permanently, and irreversibly disabling the current generating circuit upon the occurrence of a predetermined event, thereby discontinuing electrotransportation of the agent from the device.

9. The method of claim 8, wherein said predetermined event comprises the expiration of the shelf-life of the device.

10. The method of claim 8, wherein the timer circuit can be set to after a predetermined period of time fire a silicon controlled rectifier to discharge a battery to permanently and irreversibly disable the current generating circuit.

11. An electrotransport device for delivering a therapeutic agent, comprising: a power source; first and second electrodes and reservoirs, wherein at least one of the reservoirs contains the therapeutic agent; a current generating circuit; a current controlling circuit; a current enabling circuit; and current disabling means adapted to automatically, permanently and irreversibly disable the current generating circuit upon occurrence of a predetermined event, thereby discontinuing electrotransportation of the agent from the device, said disabling means including a timer, wherein said disabling means is activated after said timer measures a predetermined period of time.

12. The device of claim 11, wherein said timer is activated when said current generating circuit is first placed in operation.

13. The device of claim 11, wherein said tinier is activated when the electrotransport device is manufactured.

14. The device of claim 11, wherein the agent comprises an abusable drug.

15. The device of claim 14, wherein said abusable drug comprises a narcotic analgesic.

16. The device of claim 14, wherein said abusable drug is selected from the group consisting of fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihyrocodcinone and cocaine.

17. The device of claim 11, wherein the timer circuit can be set to after a predetermined period of time fire a silicon controlled rectifier to discharge a battery to permanently and irreversibly disable the current generating circuit.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc